stage II/III non-small cell lung cancer
Conditions
Interventions
Gold Standard:Clinical outcome/image diagnose result
Sponsors
Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Aged >=18 years old, male or female; 2. Patients with stage II/III lung cancer confirmed by histology and/or cytology; 3. acceptable for radical operation; 4. ECOG<=1; 5. Expected lifetime over 12 months; 6. Get informed consent from the patient.
Exclusion criteria
Exclusion criteria: 1. Patients who had neoadjuvant therapy before surgery; 2. Patients with other malignant tumors; 3. Patients who had Blood transfusion during or 2 weeks before surgery; 4. Patients with Any severe or uncontrolled systemic disease that significantly affects the patient's risk/benefit balance, including uncontrolled hypertension, hepatitis B, hepatitis C, AIDS, rheumatic immune diseases, etc.; 5. Baseline samples (preoperative and postoperative plasma samples, tumor tissue samples) are incomplete for a variety of reasons; 6. patients who missed 3 consecutive plasma during the whole process of detection, and the ctDNA detected at next monitoring point was positive or confirmed recurrence by imaging; 7. Have a history of alcohol abuse or drug abuse; 8. Pregnant or lactating female patient; 9. Researchers believe that it is not suitable for the group.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| ctDNA mutations;SEN, SPE, ACC; | — |
Contacts
Public ContactShugeng Gao
Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
Outcome results
None listed